Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: GlobalData
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aegerion Pharmaceuticals Inc Raises FY 2013 Revenue Guidance

Tuesday, 30 Jul 2013 07:00am EDT 

Aegerion Pharmaceuticals Inc raised fiscal 2013 revenue guidance from the previous range of $15 to $25 million, to the higher range of $30 to $35 million. The upward revision reflects the results and insights to date with respect to the launch of JUXTAPID in the U.S. Aegerion continues to expect total operating expenses, excluding stock-based compensation expense, to be between $75 and $85 million in 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $32 million for fiscal 2013. 

Company Quote

0.27 +0.99%
22 Jul 2014